New Tideworks Survey Reveals Need for Practical Data Accuracy and Connectivity at Marine Terminals
SEATTLE--(BUSINESS WIRE)--A new global survey from Tideworks Technology® (Tideworks), a full-service provider of comprehensive terminal operating systems (TOS), in partnership with Port Technology International (PTI), reveals key opportunities for practical, real-time and automated data connectivity across marine terminal operations. AI emerged as a top technology priority for large terminals, while terminals of all sizes ranked equipment and asset utilization as the two leading focus areas to improve operations.
The survey gathered responses globally from 121 professionals across container, bulk and roll-on/roll-off terminal operations, with annual throughputs ranging from under 100,000 TEUs to more than five million. Despite widespread adoption of digital tools and automation technologies, terminals still face persistent challenges with data connectivity, system integration and real-time visibility, especially those managing complex operations with lean teams. Operators are looking for connected systems that are easy to use, adaptable to their needs and built for everyday terminals.
'We see marine terminals making bold technology investments, but the next step is ensuring systems work together,' said Thomas J. Rucker, President of Tideworks Technology. 'What's needed now is smarter connectivity that links data seamlessly across systems, both within the terminal and beyond the gate. Tideworks is committed to meeting terminals where they are, helping them unify their data and operations at their own pace, while giving them the flexibility to explore other emerging technologies on their own terms.'
The findings highlight where more connected, real-time systems can deliver the greatest impact for terminal operations.
Yard Optimization is a Top Priority:
74% of terminals are focused on reducing unproductive moves and maximizing equipment use. Yard space remains a constraint, with 66% citing it as their top challenge.
Process Automation Leads, Equipment Lags:
58% of respondents rank process automation as their priority for technology initiatives, making it the top item in this category. Equipment automation is a lower priority, ranked fifth place with 35%.
Limited Connectivity Hinders Real-Time Insight:
86% of respondents utilize TOS and planning tools; however, only 30% leverage real-time analytics. Data sharing is also a barrier—53% face internal integration challenges, and 46% struggle externally. In addition, nearly half (45%) lack real-time visibility.
AI Interest Is Growing, but Data Foundations Must Improve:
Among large terminals (1M+ TEUs), 64% are prioritizing AI, compared to 43% of terminals overall. However, 58% of all terminals still rely on manual data practices, highlighting the need for cleaner, more accessible data before advanced technologies can deliver real value.
Tideworks and its leadership team will be at TOC Europe (Booth J50) in Rotterdam from June 17 -19, to share more insights from the survey and showcase its latest solutions designed to unify systems, unlock data and deliver operational optimization in real time.
View full survey insights here:
About Tideworks Technology
Tideworks is a full-service provider of comprehensive terminal operating system solutions for growing marine and intermodal rail terminal operations worldwide. The company helps more than 120 facilities run their operations more efficiently and profitably. From optimized equipment utilization to faster turn times, Tideworks works at every step of terminal operations to maximize productivity and customer service. For more information about Tideworks Technology, a Carrix solution, visit www.tideworks.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
CVMSDC Invites Small Businesses to Pursue 'Accessible Connections' During Annual Business Opportunity Conference (BOC25), Aug. 3-5 in Charleston, SC
CHARLESTON, S.C., June 18, 2025--(BUSINESS WIRE)--The Carolinas-Virginia Minority Supplier Development Council will host its 48th annual Business Opportunity Conference (BOC25) on Aug. 3-5 at the Marriott Lockwood in Charleston, South Carolina. In addition to a welcome reception hosted at the International African American Museum, the two-day business program will highlight the theme of Accessible Connections, in alignment with intentional efforts by The Council to make access and inclusion integral parts of doing business. This year's conference will feature a scholarship swing golf tournament, along with a series of workshops for corporate partners, small business owners and certified Minority Business Enterprises (MBEs) – featuring keynote speakers, networking sessions, panel discussions, Open Roundtable "Business Connections" matchmaking between corporations and business owners, an artisans vendor market and an awards reception to recognize top small business performers and corporations. CVMSDC also will recognize young entrepreneurs from the student pitch competition as part of the conference and hold a free student workshop on entrepreneurship as a career path. Registration is open with $200 off for all small business owners to attend this impactful conference. The title sponsor for BOC25 is SONOCO. CVMSDC President & CEO Dominique Milton said: "True progress begins with access. At CVMSDC, we believe that making meaningful connections isn't just about networking—it's also about breaking down barriers, unlocking opportunities, and ensuring that our small business community has access to the resources they need to develop and grow their companies." Carolinas-Virginia Minority Supplier Development Council is a non-profit corporation chartered to enhance business opportunities for small business owners and certified MBEs by providing support through developing mutually beneficial networking opportunities with corporate partners and promoting business development through its four key pillars of advocacy, certification, connections and development. For more information or to register for BOC25, visit: View source version on Contacts Media Contact: PR PROS vk@ / (336) 362-9668
Business Wire
38 minutes ago
- Business Wire
Satellos Bioscience Shareholders Elect Two New Board Members
TORONTO--(BUSINESS WIRE)-- Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (' Satellos ' or the ' Company '), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced the election of Iris Loew-Friedrich, M.D., Ph.D., and Selwyn Ho, MBBS, to its Board of Directors. 'I am so excited to welcome Dr. Loew-Friedrich and Dr. Ho to our Board at this pivotal time,' said Frank Gleeson, Satellos co-founder and CEO. 'We believe their deep expertise in global clinical and commercial development will be invaluable to Satellos as we advance SAT-3247 and realize our technology's transformative potential for the treatment of people living with Duchenne muscular dystrophy and other degenerative conditions. We look forward to drawing on their proven expertise in positioning Satellos for future partnerships and development strategies focused on delivering optimal value for shareholders.' A highly accomplished biotech and pharmaceutical executive, Dr. Loew-Friedrich is recognized as the senior clinical leader who shaped UCB into a global powerhouse in neurology and immunology. Serving as executive vice president and chief medical officer until 2024, she led UCB's worldwide development and regulatory strategy for over two decades, overseeing the global approvals of multiple blockbuster therapies, including Cimzia, Briviact, Evenity, Rystiggo, Zilbrysq, and Bimzelx. Her leadership was instrumental in advancing both common and rare disease treatments, with a deep and sustained commitment to improving outcomes for underserved patient populations. Prior to UCB, Loew-Friedrich held senior R&D roles at Schwarz Pharma, BASF Pharma, and Hoechst/Aventis, where she contributed to the development and success of market-leading drugs such as Humira, Arava, Actonel, Vimpat, and Neupro. Dr. Ho is a seasoned pharmaceutical and biotech executive with broad leadership experience across commercial strategy, business development, financing, and board governance. He has held senior roles at global companies including Dermira (Eli Lilly), UCB, Allergan (AbbVie), Novartis, and AstraZeneca, with expertise spanning ophthalmology, immunology, oncology, and dermatology. As CEO of Medigene AG, he led a strategic transformation and established and extended key partnerships with BioNTech, Regeneron, WuXi Biologics and EpimAb Biotherapeutics. Previously, as EVP & chief business officer at Connect Biopharma, he was instrumental in raising over $350 million through IPO and private funding. He also serves on the boards of Antennova Inc. and Peptomyc S.L., and as executive-in-residence at New Rhein Healthcare Investors. As part of the Annual General Meeting, Rima Al-awar, Ph.D., William Jarosz, J.D., and William McVicar, Ph.D., did not stand for reelection. 'I want to personally thank Rima, Bill and Bill for their dedicated service, thoughtful leadership and support,' said Gleeson. 'Their guidance helped position Satellos for continued progress, and we wish them all the best in their future endeavors.' About Satellos Bioscience Inc. Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. By restoring this missing dystrophin signal in DMD, SAT-3247 enables muscle stem cells to divide properly and more efficiently, promoting natural muscle repair and regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment initially for DMD. Satellos also is leveraging its proprietary discovery platform MyoReGenX™ to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. For more information, visit Notice on Forward-Looking Statements This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the potential for SAT-3247 to represent a disease modifying approach to the therapeutic treatment of people living with Duchenne; anticipated benefits to patients from a small molecule treatment for Duchenne; the advancement SAT-3247 through clinical trials; the pharmacodynamic properties and mechanism-of-action of SAT-3247; the potential of our approach in other degenerative muscle diseases; its/their prospective impact on Duchenne patients, patients with other degenerative muscle disease or muscle injury or trauma, and on muscle regeneration generally; and Satellos' technologies and drug development plans. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are 'forward-looking information or statements.' Often but not always, forward-looking information or statements can be identified by the use of words such as 'shall', 'intends', 'believe', 'plan', 'expect', 'intend', 'estimate', 'anticipate', 'potential', 'prospective' , 'assert' or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results 'may', 'might', 'can', 'could', 'would' or 'will' be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), and the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management's ability to manage and to operate the business of the Company generally, including inflation and the costs of operating a biopharma business, and those risks listed in the 'Risk Factors' section of Satellos' Annual Information Form dated March 26, 2025 (which is located on Satellos' profile at Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise. 530509798v.1
Business Wire
38 minutes ago
- Business Wire
SouthBank Legal Expands Corporate Compliance, White Collar, and Investigations Team With Hire of Former Senior ADM and Caterpillar In-House Counsel Brendan J. Gardiner
SOUTH BEND, Ind.--(BUSINESS WIRE)--SouthBank Legal is pleased to announce that Brendan J. Gardiner has joined the firm as a Partner. Based in Boston, MA, Gardiner will focus his practice on helping companies and institutions manage their compliance and regulatory exposure, including enhancing their compliance programs, conducting due diligence, leading sensitive internal investigations, and designing and implementing effective remediation plans. Gardiner joins the firm's high-profile White Collar and Investigations practice team after almost 20 years as in-house counsel for Archer Daniels Midland (ADM) and Caterpillar Inc. His move highlights an industry trend of prominent in-house lawyers returning to private practice at premier law firms. 'We are excited to have Brendan join us and bring his vast in-house experience to assist CLOs and GCs assess and navigate risk for their companies,' stated Jesse Barrett, SouthBank Legal's Washington, DC managing partner and Chambers USA -ranked White-Collar and Investigations attorney. 'Increasingly, our clients are providing us the opportunity to help them proactively manage a full array of legal, compliance, and geopolitical risks, and Brendan's experience strengthens our ability to partner with clients to understand and address those risks before they materialize. I look forward to working alongside him in advising Fortune 500 and mid-market domestic and international clients in all aspects of their compliance operations.' Before joining SouthBank Legal, Gardiner was Vice President and Deputy General Counsel for ADM, where he oversaw a global team of over 100 attorneys and legal professionals throughout 19 countries, providing a full scope of legal practices and processes to support ADM's operations across 200+ countries. Prior to that, he was Chief Litigation and Regulatory Counsel for ADM. Before joining ADM, he was Lead Counsel, International Trade and Anti-Corruption for Caterpillar Inc., where he advised the company on anti-bribery, international sanctions, and tariff-related matters. Additionally, Gardiner was Lead Regional Counsel (EMEA), based in Brussels, and Lead Business Unit Counsel (Power Generation), based in California, for Caterpillar-owned Solar Turbines, Inc. Complementing his legal background, Gardiner has considerable experience designing and implementing insurance-based solutions to manage legal, operational, and geopolitical risks, having served as Director of Insurance and Risk Management at ADM. 'I am thrilled to be joining such an impressive team of lawyers at SouthBank Legal,' stated Gardiner. 'As the range and complexity of risks that CLOs and GCs are being asked to manage grows, in-house teams are increasingly looking to skilled outside lawyers who can provide high-quality, practical, business-oriented advice in a cost structure that meets their needs. SouthBank is a recognized leader in this space, and I look forward to working with the firm's impressive and growing list of clients across all industries. I have been in their shoes and can help them think about risk holistically and design solutions to address challenges before they arise. Having Jesse, who's a former federal prosecutor, and other incredible attorneys on the same team allows us to handle any range of scenarios, including when engagement with government regulators becomes necessary.' Gardiner clerked for the Honorable Susan H. Black at the U.S. Court of Appeals for the Eleventh Circuit. He received his J.D., magna cum laude, from Notre Dame Law School, where he was the Law Review Executive Editor, and his B.A. from the University of Notre Dame. Gardiner is the latest addition to SouthBank Legal's growing team. Most recently, the firm announced the addition of Maggie King and Gregory Guest. King, a recognized leader in the evolving legal and regulatory frameworks surrounding AI and data, focuses on technology, AI, and intellectual property aspects of business and corporate matters, including licensing and M&A projects. She also counsels clients on governance, risk management, and regulatory compliance related to generative AI, cryptocurrency, and sensitive data. An experienced data scientist, King practiced in a Tier 1 Technology Law group at a top ranked Am Law 100 firm and served as a clerk for Judge Thomas L. Kirsch II on the U.S. Court of Appeals for the Seventh Circuit. Guest has extensive experience with buyers and sellers in both financial and strategic acquisitions, and serves as advisor to entrepreneurs, investors, and closely held businesses. In addition, he advises on corporate workouts and restructuring. Guest clerked for the Honorable Lee M. Jackwig on the U.S. Bankruptcy Court for the Southern District of Iowa and practiced at an Am Law 200 firm in Michigan. SouthBank Legal, a Chambers USA ranked firm, routinely delivers smart, cost-effective business solutions to Fortune 500 global leaders as well as early-stage industry disrupters, guiding and fighting for clients in their highest-profile, highest-risk litigation from its offices in Washington, DC, Grand Rapids, MI, and northern Indiana. For more information, please visit
